Table 1. Baseline characteristics of the 61 Crohn’s disease patients, who responded to the induction anti-tumor necrosis factor therapy (primary responders), which comprised the final study group.
| Feature | n=61 |
|---|---|
| Age [mean ± SD] | 32 ± 10 |
| Male/female | 29/32 |
| Disease duration (years) [mean ± SD] | 6 ± 4 |
| C-reactive protein (mg/l) [mean ± SD] | 22.1 ± 26.1 |
| Erythrocyte sedimentation rate (mm/h) [mean ± SD] | 32 ± 20 |
| Red blood cell count (106/mm3) [mean ± SD] | 4.4 ± 0.7 |
| Hemoglobin (g/dl) [mean ± SD] | 12.3 ± 2.2 |
| Hematocrit (%) [mean ± SD] | 37 ± 5 |
| White blood cell count (103/mm3) [mean ± SD] | 7.5 ± 3.7 |
| Platelets (103/mm3) [mean ± SD] | 358 ± 109 |
| Body mass index (kg/m2) [mean ± SD] | 20.9 ± 3.3 |
| Crohn’s Disease Activity Index [median (95%CI)] | 267 (232 – 292) |
| Simple Endoscopic Score for CD (SES-CD) [median (95%CI)] | 12 (11 – 18) |
| Ileal SES-CD [median (95%CI)] | 5 (4 – 7) |
| Colonic SES-CD [median (95%CI)] | 8 (7 – 13) |
| Previous surgery – n (%) | 24/61 (39%) |
| Disease location – n (%) | |
| L1 (ileal) | 26/61 (43%) |
| L3 (ileocolonic) | 35/61 (57%) |
| Disease behavior – n (%) | |
| B1 (inflammatory) | 32/61 (53%) |
| B2 (stricturing) | 10/61 (16%) |
| B3 (penetrating) | 19/61 (31%) |
| Medications | |
| Steroids | 26/61 (42%) |
| Azathioprine | 53/61 (87%) |
| Aminosalicylates | 60/61 (98%) |
| Probiotics | 46/61 (75%) |
| Antibiotics | 15/61 (24%) |
| Previous anti-TNF therapy | 8/61 (13%) |
Data are presented as means with standard deviations (SD) or medians with 95% confidence intervals (CI).